K Huebner Selected Research

fragile histidine triad protein

11/2001	Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.
5/2001	Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice.
3/2001	FHIT gene expression in human urinary bladder transitional cell carcinomas.
1/2001	Fhit protein expression in hereditary and sporadic colorectal cancers.
1/2001	Fhit protein expression in endometrial cancers: no correlation with histological grade.
10/2000	Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival.
10/2000	Expression of Fhit protein during mouse development.
8/2000	Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer.
4/2000	Muir-Torre-like syndrome in Fhit-deficient mice.
3/2000	Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

K Huebner Research Topics

Disease

24	Neoplasms (Cancer) 01/2017 - 01/2000
4	Carcinogenesis 01/2007 - 08/2000
3	Carcinoma (Carcinomatosis) 10/2000 - 01/2000
2	Lung Neoplasms (Lung Cancer) 03/2020 - 05/2006
2	Squamous Cell Carcinoma of Head and Neck 07/2001 - 07/2001
2	Esophageal Neoplasms (Esophageal Cancer) 02/2001 - 08/2000
1	Infections 05/2006
1	Oral Lichen Planus 07/2001
1	Pancreatic Neoplasms (Pancreatic Cancer) 06/2001
1	Thyroid Neoplasms (Thyroid Cancer) 05/2001
1	Endometrial Neoplasms (Endometrial Cancer) 01/2001
1	Colorectal Neoplasms (Colorectal Cancer) 01/2001
1	Breast Neoplasms (Breast Cancer) 08/2000
1	Renal Cell Carcinoma (Grawitz Tumor) 06/2000
1	Urinary Bladder Neoplasms (Bladder Cancer) 02/2000
1	Adenocarcinoma 01/2000
1	Stomach Neoplasms (Stomach Cancer) 01/2000

Drug/Important Bio-Agent (IBA)

11	fragile histidine triad proteinIBA 11/2001 - 01/2000
7	Histidine (L-Histidine)FDA Link 05/2006 - 06/2000
5	CarcinogensIBA 01/2007 - 01/2000
4	Proteins (Proteins, Gene)FDA Link 05/2003 - 05/2001
2	Tyrosine (L-Tyrosine)FDA Link 03/2020 - 05/2006
2	SurvivinIBA 03/2020 - 05/2006
2	nitrosobenzylmethylamineIBA 08/2001 - 08/2000
2	Environmental CarcinogensIBA 03/2000 - 02/2000
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2017
1	WW Domain-Containing OxidoreductaseIBA 01/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	Complementary DNA (cDNA)IBA 01/2007
1	PolyphosphatesIBA 05/2006
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 11/2004
1	RNA (Ribonucleic Acid)IBA 07/2001
1	Immune Sera (Antisera)IBA 07/2001
1	AphidicolinIBA 05/2001
1	Biological ProductsIBA 02/2001
1	dimemorfan (AT 17)IBA 10/2000
1	ZincIBA 08/2000
1	Cyclin-Dependent Kinase 4IBA 08/2000
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2000
1	Tumor Biomarkers (Tumor Markers)IBA 01/2000
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2000
1	Indicators and Reagents (Reagents)IBA 01/2000

Therapy/Procedure

2	Therapeutics 11/2001 - 02/2001
1	Aftercare (After-Treatment) 08/2001